These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9796990)

  • 1. Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy.
    Dolman CS; Mueller BM; Lode HN; Xiang R; Gillies SD; Reisfeld RA
    Clin Cancer Res; 1998 Oct; 4(10):2551-7. PubMed ID: 9796990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases.
    Xiang R; Lode HN; Dreier T; Gillies SD; Reisfeld RA
    Cancer Res; 1998 Sep; 58(17):3918-25. PubMed ID: 9731503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
    Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
    Eisenthal A; Cameron RB; Uppenkamp I; Rosenberg SA
    Cancer Res; 1988 Dec; 48(24 Pt 1):7140-5. PubMed ID: 3263900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
    Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
    Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases.
    Gillies SD; Lan Y; Wesolowski JS; Qian X; Reisfeld RA; Holden S; Super M; Lo KM
    J Immunol; 1998 Jun; 160(12):6195-203. PubMed ID: 9637539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
    Dreier T; Lode HN; Xiang R; Dolman CS; Reisfeld RA; Kang AS
    Bioconjug Chem; 1998; 9(4):482-9. PubMed ID: 9667950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
    Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
    Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer.
    Wagner K; Schulz P; Scholz A; Wiedenmann B; Menrad A
    Clin Cancer Res; 2008 Aug; 14(15):4951-60. PubMed ID: 18676770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
    Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
    Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy.
    Christ O; Seiter S; Matzku S; Burger C; Zöller M
    Clin Cancer Res; 2001 Apr; 7(4):985-98. PubMed ID: 11309350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy.
    Xiang R; Lode HN; Dolman CS; Dreier T; Varki NM; Qian X; Lo KM; Lan Y; Super M; Gillies SD; Reisfeld RA
    Cancer Res; 1997 Nov; 57(21):4948-55. PubMed ID: 9354462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human CD4+ effector T cells mediate indirect interleukin-12- and interferon-gamma-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice.
    Egilmez NK; Hess SD; Chen FA; Takita H; Conway TF; Bankert RB
    Cancer Res; 2002 May; 62(9):2611-7. PubMed ID: 11980657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model.
    Nasu Y; Bangma CH; Hull GW; Lee HM; Hu J; Wang J; McCurdy MA; Shimura S; Yang G; Timme TL; Thompson TC
    Gene Ther; 1999 Mar; 6(3):338-49. PubMed ID: 10435084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
    Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
    Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
    Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.